Effects of the Antiestrogens Tamoxifen, Toremifene, and ICI 182,780 on Endometrial Cancer Growth
- 21 October 1998
- journal article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 90 (20), 1552-1558
- https://doi.org/10.1093/jnci/90.20.1552
Abstract
Background: Tamoxifen has been shown to promote the growth of human endometrial tumors implanted in athymic mice, and it has been associated with a twofold to threefold increase in endometrial cancer. Toremifene, a chlorinated derivative of tamoxifen, and ICI 182,780, a pure antiestrogen, are two new antiestrogens being developed for the treatment of breast cancer. The effects of these drugs on endometrial cancer are currently unknown. Our objective was to evaluate the effects of toremifene and ICI 182,780 on the growth of human endometrial cancer in athymic mice. Methods: Athymic, ovariectomized mice were implanted with human endometrial tumors and treated with estrogen, tamoxifen, or the new antiestrogens. Results: The effects of tamoxifen and toremifene on the growth of either tamoxifenstimulated or tamoxifen-naive endometrial tumors in athymic mice were not substantially different. ICI 182,780 inhibited the growth of tamoxifen-stimulated endometrial cancer, in both the presence and the absence of estrogen. Conclusions: Toremifene and tamoxifen produce identical effects in our endometrial cancer models. Therefore, it is possible that toremifene, like tamoxifen, may be associated with an increased incidence of endometrial cancer. In contrast, ICI 182,780 inhibited tamoxifen-stimulated endometrial cancer, both in the presence and in the absence of estrogen, suggesting that this drug may be safe with regard to the endometrium, even if it is used following tamoxifen, and that it may not result in an increased incidence of endometrial cancer. Indeed, it is even possible that ICI 182,780 may prove useful as an adjuvant agent in early stage endometrial cancer. [J Nall Cancer Inst 1998;90:1552-8]Keywords
This publication has 21 references indexed in Scilit:
- Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI 182780 in women with advanced breast cancerBritish Journal of Cancer, 1996
- Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.Journal of Clinical Oncology, 1995
- Direct determination of tamoxifen and its four major metabolites in plasma using coupled column high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1994
- Tamoxifen induces hepatocellular carcinoma in rat liver: A 1-year study with two antiestrogensArchives of Toxicology, 1993
- ICI 182,780, a new antioestrogen with clinical potentialThe Journal of Steroid Biochemistry and Molecular Biology, 1992
- Phase II clinical study of toremifene in patients with metastatic breast cancer. Preliminary communicationJournal of Steroid Biochemistry, 1990
- ADJUVANT TAMOXIFEN IN EARLY BREAST CANCER: OCCURRENCE OF NEW PRIMARY CANCERSThe Lancet, 1989
- Effects of Adjuvant Tamoxifen and of Cytotoxic Therapy on Mortality in Early Breast CancerNew England Journal of Medicine, 1988
- Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II studyEuropean Journal of Cancer and Clinical Oncology, 1988
- NECROPSY DIAGNOSIS OF ENDOMETRIAL CANCER AND DETECTION-BIAS IN CASE/CONTROL STUDIESThe Lancet, 1981